Cancer Care


Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Principal Investigator (?)
Study Number
The main goal of the research study is to determine whether treating renal cell cancer
patients with the study drug, hydroxychloroquine, along with IL-2, a standard treatment of
kidney cancer that has spread to other parts of the body, can make the cancer easier to kill
and eliminate. Another goal is to see how the study drug affects the body''s immune cells
which fight cancer cells.
Phase (?)
Phase I/II
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.